Earnings Preview For Euroseas

  Euroseas (NASDAQ:ESEA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. Analysts estimate that Euroseas will report an earnings per share (EPS) of $3.80.

 

Euroseas (NASDAQ:ESEA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here’s what investors need to know before the announcement.

Analysts estimate that Euroseas will report an earnings per share (EPS) of $3.80.

Euroseas bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company beat EPS by $0.10, which was followed by a 8.24% increase in the share price the next day.

Here’s a look at Euroseas’s past performance and the resulting price change:

 

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate 3.6 3.23 1.39 0.91
EPS Actual 3.7 3.17 1.16 1.12
Price Change % 8.24% -6.46% -3.62% -1.88%

eps graph

Stock Performance

Shares of Euroseas were trading at $25.38 as of August 08. Over the last 52-week period, shares are up 21.56%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for Euroseas visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval

Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are expected to be at least $13.6m for the whole of the fiscal year, a 433% YoY increase. Its subsidiary B.I. Sky Global drove the increase in sales. Innocan is currently pursuing FDA approval for its human pharmaceutical applications following successful pre-clinical trials, and the company expects pre-investigational new drug applications to be submitted to the FDA before the end of the month. Innocan has developed a long-lasting and therapeutic liposomal formulation for CBD called LPT Solution, which administers injectable CBD encapsulated in liposomes to achieve long-lasting therapeutic levels of CBD in the body. The company said the technology creates a more effective and prolonged therapeutic effect. Innocan plans to test the LPT platform on a new animal species in the near future.

CSE:INNO